Sorteer per
Keyphrases
Antithymocyte Globulin
91%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
60%
Immune Reconstitution
52%
Pediatric
47%
Graft-versus-host Disease (GvHD)
38%
Individualized Dosing
35%
Hematopoietic Cell Transplantation
32%
Cord Blood Transplantation
31%
T Cells
27%
Population Pharmacokinetics
26%
Thymoglobulin
21%
Hazard Ratio
18%
Pharmacodynamics
17%
T Cell Reconstitution
17%
CD4+
16%
Therapeutic Drug Monitoring
15%
Improved Survival
15%
Serotherapy
15%
Dosing Regimen
15%
Alemtuzumab
13%
Survival Outcomes
13%
Haemopoietic Stem Cell Transplantation
13%
Unrelated Cord Blood Transplantation
13%
Melphalan
13%
Cohort Analysis
13%
Older Adults
13%
Hematological Malignancies
13%
Improved Outcomes
12%
Graft Failure
11%
Conditioning Regimen
11%
Overall Survival
10%
Hematopoietic Stem Cell Transplantation
10%
Human Herpesvirus 6 (HHV-6)
9%
Area under the Curve
9%
Viral Reactivation
9%
Pharmacokinetics
9%
High Risk
8%
Reconstitution
8%
Parachute
8%
Fludarabine
7%
Pediatric Oncology
7%
T Cell Survival
7%
Acute Leukemia
7%
Evidence-based
7%
Acute Lymphoblastic Leukemia
7%
Large Cohort
7%
Chimeric Antigen Receptor T-cell Therapy
6%
Globulin
6%
High Dose
6%
Conditioning Regime
6%
Immunology and Microbiology
Anti-Thymocyte Globulin
100%
T Cell
58%
Immune Reconstitution
50%
Cell Transplantation
45%
Hematopoietic Cell
32%
Cord Blood Stem Cell Transplantation
32%
Graft-Versus-Host Disease
25%
CD4
24%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Pharmacokinetics
16%
Conditioning
15%
Pharmacodynamics
13%
Leporidae
13%
Thymocyte
13%
Overall Survival
12%
Hematopoietic Stem Cell Transplantation
10%
Human Herpesvirus 6
9%
Arm
8%
Blood Plasma
8%
Alemtuzumab
8%
Acute Graft Versus Host Disease
8%
Myeloid
7%
Liquid Chromatography Tandem Mass Spectrometry
6%
Immunosuppression
6%
Filgrastim
6%
Engraftment
6%
Drug Megadose
6%
Viremia
6%
Stem Cell Transplantation
6%
Systemic Scleroderma
6%
Allogeneic Stem Cell Transplantation
6%
Autologous Hematopoietic Stem Cell Transplantation
6%
Globulin
6%
T-Helper Cell
6%
Adenoviridae
6%
Event Free Survival
5%
Natural Killer Cell
5%
Cytomegalovirus
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thymocyte Antibody
66%
Pharmacokinetics
33%
Therapeutic Drug Monitoring
17%
Graft Versus Host Reaction
15%
Alemtuzumab
14%
Globulin
13%
Melphalan
13%
Pharmacodynamics
11%
Graft Failure
8%
Acute Lymphoblastic Leukemia
8%
Disease
8%
Overall Survival
7%
Acute Leukemia
6%
Rhabdomyosarcoma
6%
Systemic Sclerosis
6%
Chimeric Antigen Receptor
6%
Pharmacotherapy
6%
Pharmacodynamic Modeling
6%
High Dose Chemotherapy
6%
Fludarabine
6%
Leporidae
6%
Hematologic Malignancy
6%
Controlled Clinical Trial
5%
Infection
5%
